Stocks › LGND
LIGAND PHARMACEUTICALS INC
LGND·Nasdaq·
United States·USD
United States·USD$293.26
-3.68 (-1.24%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
LGND
LIGAND PHARMACEUTICALS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
LGNDS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of LGND by members of U.S. Congress · 16 on record · 4 in the last 12 months
Whale Activity
Position changes in LGND reported for 2026-09-30 by 2 tracked institutional filers
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| CONGRESS ASSET MANAGEMENT CO | 658.6K | $205.7M | — |
| MOODY NATIONAL BANK TRUST DIVISION | 13.9K | $4.3M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by LGND insiders, by quarter · Form 4
Recent Insider Transactions
1,895 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Reardon AndrewCLO & Secretary | Sale | −833 | $302.51 | $252K | Oct 2, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −404 | $306.18 | $124K | Oct 2, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −235 | $307.19 | $72K | Oct 2, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −1,976 | $303.54 | $600K | Oct 2, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −17 | $307.74 | $5K | Oct 2, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −1,535 | $304.52 | $467K | Oct 2, 2026 | Form 4 ↗ |
| Zimmermann MartineDirector · Director | Sale | −1,200 | $285.00 | $342K | Sep 10, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −400 | $288.98 | $116K | Sep 3, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −385 | $287.53 | $111K | Sep 3, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −300 | $283.99 | $85K | Sep 3, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −2,115 | $286.36 | $606K | Sep 3, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −1,800 | $285.17 | $513K | Sep 3, 2026 | Form 4 ↗ |
| Espinoza OctavioChief Financial Officer | Sale | −31.6K | $292.06 | $9.2M | Aug 12, 2026 | Form 4 ↗ |
| Haas JasonDirector · Director | Sale | −7,138 | $292.81 | $2.1M | Aug 12, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −991 | $291.71 | $289K | Aug 3, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −503 | $289.80 | $146K | Aug 3, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −409 | $292.82 | $120K | Aug 3, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −356 | $288.75 | $103K | Aug 3, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −33 | $284.55 | $9K | Aug 3, 2026 | Form 4 ↗ |
| Reardon AndrewCLO & Secretary | Sale | −200 | $290.60 | $58K | Aug 3, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding LGND · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 1.2M | $381.6M | 0.34% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 605.7K | $191.5M | 0.01% | Jun 30, 2026 |
| Franklin Dynatech Fund Franklin Custodian Funds | 550.0K | $173.8M | 0.58% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 515.6K | $163.0M | 0.20% | Jun 30, 2026 |
| Janus Henderson Triton Fund Janus Investment Fund | 494.3K | $156.2M | 2.63% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 436.8K | $138.1M | 0.07% | Jun 30, 2026 |
| Invesco Discovery Fund AIM Counselor Series Trust (Invesco Counselor Series Trust) | 519.2K | $120.4M | 1.54% | May 31, 2026 |
| Fidelity Small Cap Value Fund Fidelity Securities Fund | 325.7K | $93.6M | 1.71% | Jul 31, 2026 |
| Nomura Small Cap Core Fund Delaware Group Equity Funds V | 385.3K | $89.4M | 1.62% | May 29, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 276.6K | $87.4M | 0.13% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list LGND's shares (CUSIP 53220K504), each fund at its latest report since Mar 8, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming LIGAND PHARMACEUTICALS INC as client
No lobbying filings found naming LIGAND PHARMACEUTICALS INC as the client.
Government Contracts
Federal awards to LIGAND PHARMACEUTICALS INC · USAspending
No federal contract awards found for LIGAND PHARMACEUTICALS INC.
U.S. Patents
Recent USPTO applications naming LIGAND PHARMACEUTICALS INC
No USPTO patent applications found for LIGAND PHARMACEUTICALS INC.
Annual Financials
From LGND's 10-K filings · XBRL
No annual XBRL figures on record for LGND. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in LGND's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 8.01Reg FD disclosure · Other eventsSep 24, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 22, 2026
EDGAR ↗ - 8-K/A · Items 9.01Sep 2, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.01, 2.03, 7.01, 9.01Material agreement · Acquisition or disposition · Direct financial obligationJul 14, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 3.02, 8.01, 9.01Material agreement · Direct financial obligation · Unregistered sale of equityJun 25, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsJun 22, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07Officer / director change · Shareholder voteJun 9, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementMay 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗
About LIGAND PHARMACEUTICALS INC
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0000886163 ↗
Former namesLIGAND PHARMACEUTICALS